720
Participants
Start Date
March 23, 2018
Primary Completion Date
January 31, 2026
Study Completion Date
January 31, 2027
Olaparib
300mg taken twice daily
Dasatinib
100mg administered orally once daily
Nivolumab plus Ipilimumab
"* Combination Phase - 3mg/kg nivolumab administered as an intravenous infusion over 30 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 1mg/kg administered intravenously over 30 minutes, followed by the single-agent phase.~* Single-Agent Phase - 480mg nivolumab administered as an intravenous infusion over 30 minutes every 4 weeks."
Axitinib
5mg orally twice daily
Bosutinib
500mg orally once daily
Crizotinib
250mg orally twice daily
Palbociclib
125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
Sunitinib
50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off
Temsirolimus
25mg infused over a 30-60 minute period once a week
Erlotinib
150mg orally, once daily
Trastuzumab plus Pertuzumab
"Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.~Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes."
Vemurafenib plus Cobimetinib
"Vemurafenib = 960 mg orally every 12 hours.~Cobimetinib = 60 mg orally once daily for 21 days, followed by 7 days of rest"
Vismodegib
150mg taken orally, once daily
Tucatinib
300mg taken orally, twice daily
RECRUITING
Cross Cancer Institute, Edmonton
RECRUITING
BCCA - Kelowna, Kelowna
RECRUITING
BCCA - Vancouver, Vancouver
RECRUITING
Kingston Health Sciences Centre, Kingston
RECRUITING
London Health Sciences Centre Research Inc., London
RECRUITING
Ottawa Hospital Research Institute, Ottawa
RECRUITING
University Health Network, Toronto
RECRUITING
The Jewish General Hospital, Montreal
RECRUITING
Allan Blair Cancer Centre, Regina
RECRUITING
Saskatoon Cancer Centre, Saskatoon
Collaborators (3)
AstraZeneca
INDUSTRY
Bristol-Myers Squibb
INDUSTRY
Hoffmann-La Roche
INDUSTRY
Pfizer
INDUSTRY
Seagen Inc.
INDUSTRY
Canadian Cancer Trials Group
NETWORK